NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

下一代癌症診斷市場調查報告:各技術,各癌症類型,各功能,各用途-至2025年的預測-COVID-19累積的影響

Next Generation Cancer Diagnostics Market Research Report by Technology, by Cancer Type, by Function, by Application, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

出版商 360iResearch LLP 商品編碼 998433
出版日期 內容資訊 英文 192 Pages
商品交期: 最快1-2個工作天內
價格
下一代癌症診斷市場調查報告:各技術,各癌症類型,各功能,各用途-至2025年的預測-COVID-19累積的影響 Next Generation Cancer Diagnostics Market Research Report by Technology, by Cancer Type, by Function, by Application, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19
出版日期: 2021年06月01日內容資訊: 英文 192 Pages
簡介

全球下一代癌症診斷的市場規模,2020年為56億9,379萬美元/49億9,242萬歐元。該市場,預計至2025年末達157億3,827萬美元/137億9,961萬歐元。

COVID-19是影響幾乎全部產業的無與倫比的世界公共衛生緊急事件,在預測期間內預計帶給產業的成長長期性的影響。目前進行的調查擴大了框架,以確保包括潛在的COVID-19問題和發展途徑。本報告提供有關COVID-19的見解,其中考慮了消費者行為和需求的變化,購買方式,供應鏈的新路由,當前市場力量的動態以及政府的重要介入等COVID-19對市場的影響相關洞察。

本報告提供下一代癌症診斷市場相關調查,市場概要,以及各技術,各癌症類型,各功能,各用途,各地區的趨勢,COVID-19累積的影響,及加入此市場的主要企業簡介等資訊。

目錄

第1章 序文

  • 調查的目的
  • 市場區隔和範圍
  • 調查對象年
  • 貨幣和價格
  • 語言
  • 限制事項
  • 利害關係者

第2章 調查手法

  • 調查流程
    • 定義:調查目的
    • 決策:調查設計
    • 準備:調查設備
    • 收集:資料來源
    • 分析:資料的解釋
    • 制定:資料檢驗
    • 公開:調查報告
    • 重複:報告的更新
  • 調查的實行
    • 開始:調查流程
    • 計劃:調查計劃作成
    • 實行:調查實施
    • 檢驗:發現與分析
    • 出版物:調查報告
  • 調查成果

第3章 摘要整理

  • 簡介
  • 市場預測
  • 各癌症類型預測
  • 各技術預測
  • 各功能預測
  • 各用途預測
  • 各地區預測
  • 其他各競爭公司預測

第4章 市場概要

  • 簡介
  • COVID-19累積的影響

第5章 市場洞察

  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 課題
  • 波特五力分析
    • 新加入業者的威脅
    • 替代品的威脅
    • 客戶談判力
    • 供給企業談判力
    • 產業的競爭

第6章 全球下一代癌症診斷市場,各技術

  • DNA微陣列
  • 實驗室晶片及逆轉錄酵素-PCR
  • 次世代定序
  • 蛋白質微陣列
  • qPCR與多重化

第7章 全球下一代癌症診斷市場,各癌症類型

  • 乳癌
  • 子宮頸癌
  • 大腸癌
  • 肺癌

第8章 全球下一代癌症診斷市場,各功能

  • 癌症診察
  • 搭配診斷
  • 預後
  • 風險分析
  • 治療監測

第9章 全球下一代癌症診斷市場,各用途

  • 生物標記的開發
  • CTC分析
  • 表觀遺傳分析
  • 遺傳基因分析
  • 蛋白質體學分析

第10章 南北美洲的下一代癌症診斷市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章 亞太地區的下一代癌症診斷市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 韓國
  • 泰國

第12章 歐洲,中東、非洲的下一代癌症診斷市場

  • 法國
  • 德國
  • 義大利
  • 荷蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 阿拉伯聯合大公國
  • 英國

第13章 競爭情形

  • FPNV定位矩陣
    • 象限
    • 事業策略
    • 產品的滿意度
  • 市場排行榜分析
  • 市場佔有率分析
  • 其他競爭公司的SWOT分析
  • 競爭模式
    • 合併和收購
    • 協定,合作,及夥伴關係
    • 新產品的銷售與強化
    • 投資與資金籌措
    • 獎,獎勵,擴大

第14章 企業的實用性簡介

  • Abbott Laboratories
  • Adaptive Biotechnologies Inc.
  • Agendia Nv
  • Agilent Technologies, Inc
  • Akadeum Life Sciences
  • Almac Group
  • Ambry Genetics
  • Becton, Dickinson And Co.
  • Biological Dynamics Inc.
  • Castle Biosciences Inc.
  • Danaher Corporation
  • Exosome Diagnostics, Inc.
  • F. Hoffmann-La Roche Ltd
  • GE Healthcare
  • Genomic Health, Inc.
  • Hologic, Inc
  • Illumina, Inc.
  • Janssen Global Services, LLC
  • Koninklijke Philips N.V.
  • Myriad Genetics, Inc.
  • Novartis AG
  • Opko Health, Inc.
  • Perkin Elmer, Inc.
  • Qiagen N.V.
  • Sysmex Corporation
  • Thermo Fisher Scientific, Inc.

第15章 附錄

  • 討論指南
  • 許可證和價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MRR-AD36CD89857B

The Global Next Generation Cancer Diagnostics Market size was estimated at USD 5,693.78 Million in 2020 and expected to reach USD 7,006.17 Million in 2021, at a Compound Annual Growth Rate (CAGR) 23.38% to reach USD 20,092.53 Million by 2026.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Next Generation Cancer Diagnostics to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Technology, the Next Generation Cancer Diagnostics Market was studied across DNA Microarrays, Lab-on- a- chip & Reverse Transcriptase-PCR, Next Generation Sequencing, Protein Microarrays, and qPCR & Multiplexing.

Based on Cancer Type, the Next Generation Cancer Diagnostics Market was studied across Breast Cancer, Cervical Cancer, Colorectal Cancer, and Lung Cancer.

Based on Function, the Next Generation Cancer Diagnostics Market was studied across Cancer Screening, Companion Diagnostics, Prognostics, Risk Analysis, and Therapeutic Monitoring.

Based on Application , the Next Generation Cancer Diagnostics Market was studied across Biomarker Development, CTC Analysis, Epigenetic Analysis, Genetic Analysis, and Proteomic Analysis.

Based on Geography, the Next Generation Cancer Diagnostics Market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Next Generation Cancer Diagnostics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Next Generation Cancer Diagnostics Market, including Abbott Laboratories, Adaptive Biotechnologies Inc., Agendia Nv, Agilent Technologies, Inc, Akadeum Life Sciences, Almac Group, Ambry Genetics, Becton, Dickinson And Co., Biological Dynamics Inc., Castle Biosciences Inc., Danaher Corporation, Exosome Diagnostics, Inc., F. Hoffmann-La Roche Ltd, GE Healthcare, Genomic Health, Inc., Hologic, Inc, Illumina, Inc., Janssen Global Services, LLC, Koninklijke Philips N.V., Myriad Genetics, Inc., Novartis AG, Opko Health, Inc., Perkin Elmer, Inc., Qiagen N.V., Sysmex Corporation, and Thermo Fisher Scientific, Inc..

The report provides insights on the following pointers:

  • 1. Market Penetration: Provides comprehensive information on the market offered by the key players
  • 2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
  • 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
  • 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
  • 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

  • 1. What is the market size and forecast of the Global Next Generation Cancer Diagnostics Market?
  • 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Next Generation Cancer Diagnostics Market during the forecast period?
  • 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Next Generation Cancer Diagnostics Market?
  • 4. What is the competitive strategic window for opportunities in the Global Next Generation Cancer Diagnostics Market?
  • 5. What are the technology trends and regulatory frameworks in the Global Next Generation Cancer Diagnostics Market?
  • 6. What is the market share of the leading vendors in the Global Next Generation Cancer Diagnostics Market?
  • 7. What modes and strategic moves are considered suitable for entering the Global Next Generation Cancer Diagnostics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

  • 3.1. Introduction
  • 3.2. Market Outlook
  • 3.3. Cancer Type Outlook
  • 3.4. Technology Outlook
  • 3.5. Function Outlook
  • 3.6. Application Outlook
  • 3.7. Geography Outlook
  • 3.8. Competitor Outlook

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidence of oncology diseases
      • 5.1.1.2. Significantly decreasing cost of genetic sequencing
      • 5.1.1.3. Benefits of cluster chip technology and applications of CTC in cancer management
    • 5.1.2. Restraints
      • 5.1.2.1. Need for expensive laboratory set-up
      • 5.1.2.2. Insufficient reimbursement policies for innovative technologies
    • 5.1.3. Opportunities
      • 5.1.3.1. Government support in a number of research projects in oncology and preventative diagnosis
      • 5.1.3.2. Potential CTC enumeration sectors to monitor tumorigenesis
    • 5.1.4. Challenges
      • 5.1.4.1. Shortage of helium and increased cost of diagnostic imaging systems
  • 5.2. Cumulative Impact of COVID-19
  • 5.3. Porters Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry

6. Next Generation Cancer Diagnostics Market, by Technology

  • 6.1. Introduction
  • 6.2. DNA Microarrays
  • 6.3. Lab-on- a- chip & Reverse Transcriptase-PCR
  • 6.4. Next Generation Sequencing
  • 6.5. Protein Microarrays
  • 6.6. qPCR & Multiplexing

7. Next Generation Cancer Diagnostics Market, by Cancer Type

  • 7.1. Introduction
  • 7.2. Breast Cancer
  • 7.3. Cervical Cancer
  • 7.4. Colorectal Cancer
  • 7.5. Lung Cancer

8. Next Generation Cancer Diagnostics Market, by Function

  • 8.1. Introduction
  • 8.2. Cancer Screening
  • 8.3. Companion Diagnostics
  • 8.4. Prognostics
  • 8.5. Risk Analysis
  • 8.6. Therapeutic Monitoring

9. Next Generation Cancer Diagnostics Market, by Application

  • 9.1. Introduction
  • 9.2. Biomarker Development
  • 9.3. CTC Analysis
  • 9.4. Epigenetic Analysis
  • 9.5. Genetic Analysis
  • 9.6. Proteomic Analysis

10. Americas Next Generation Cancer Diagnostics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States
    • 10.6.1. California
    • 10.6.2. Florida
    • 10.6.3. Illinois
    • 10.6.4. New York
    • 10.6.5. Ohio
    • 10.6.6. Pennsylvania
    • 10.6.7. Texas

11. Asia-Pacific Next Generation Cancer Diagnostics Market

  • 11.1. Introduction
  • 11.2. China
  • 11.3. India
  • 11.4. Indonesia
  • 11.5. Japan
  • 11.6. Malaysia
  • 11.7. Philippines
  • 11.8. South Korea
  • 11.9. Thailand

12. Europe, Middle East & Africa Next Generation Cancer Diagnostics Market

  • 12.1. Introduction
  • 12.2. France
  • 12.3. Germany
  • 12.4. Italy
  • 12.5. Netherlands
  • 12.6. Qatar
  • 12.7. Russia
  • 12.8. Saudi Arabia
  • 12.9. South Africa
  • 12.10. Spain
  • 12.11. United Arab Emirates
  • 12.12. United Kingdom

13. Competitive Landscape

  • 13.1. FPNV Positioning Matrix
    • 13.1.1. Quadrants
    • 13.1.2. Business Strategy
    • 13.1.3. Product Satisfaction
  • 13.2. Market Ranking Analysis
  • 13.3. Market Share Analysis, By Quadrant
  • 13.4. Market Share Analysis, By Company
  • 13.5. Competitive Scenario
    • 13.5.1. Merger & Acquisition
    • 13.5.2. Agreement, Collaboration, & Partnership
    • 13.5.3. New Product Launch & Enhancement
    • 13.5.4. Investment & Funding
    • 13.5.5. Award, Recognition, & Expansion

14. Company Usability Profiles

  • 14.1. Abbott Laboratories
  • 14.2. Adaptive Biotechnologies Inc.
  • 14.3. Agendia Nv
  • 14.4. Agilent Technologies, Inc
  • 14.5. Akadeum Life Sciences
  • 14.6. Almac Group
  • 14.7. Ambry Genetics
  • 14.8. Becton, Dickinson And Co.
  • 14.9. Biological Dynamics Inc.
  • 14.10. Castle Biosciences Inc.
  • 14.11. Danaher Corporation
  • 14.12. Exosome Diagnostics, Inc.
  • 14.13. F. Hoffmann-La Roche Ltd
  • 14.14. GE Healthcare
  • 14.15. Genomic Health, Inc.
  • 14.16. Hologic, Inc
  • 14.17. Illumina, Inc.
  • 14.18. Janssen Global Services, LLC
  • 14.19. Koninklijke Philips N.V.
  • 14.20. Myriad Genetics, Inc.
  • 14.21. Novartis AG
  • 14.22. Opko Health, Inc.
  • 14.23. Perkin Elmer, Inc.
  • 14.24. Qiagen N.V.
  • 14.25. Sysmex Corporation
  • 14.26. Thermo Fisher Scientific, Inc.

15. Appendix

  • 15.1. Discussion Guide
  • 15.2. License & Pricing
  • 15.3. Contact Details

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2020 VS 2026 (USD MILLION)
  • FIGURE 2. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2020 (USD MILLION)
  • FIGURE 3. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2020 (USD MILLION)
  • FIGURE 4. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2020 (USD MILLION)
  • FIGURE 5. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2020 (USD MILLION)
  • FIGURE 6. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
  • FIGURE 7. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET: MARKET DYNAMICS
  • FIGURE 8. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET: PORTERS FIVE FORCES ANALYSIS
  • FIGURE 9. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2020 VS 2026 (%)
  • FIGURE 10. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2020 VS 2026 (USD MILLION)
  • FIGURE 11. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2026
  • FIGURE 12. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY DNA MICROARRAYS, 2018-2026 (USD MILLION)
  • FIGURE 13. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY DNA MICROARRAYS, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 14. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LAB-ON- A- CHIP & REVERSE TRANSCRIPTASE-PCR, 2018-2026 (USD MILLION)
  • FIGURE 15. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LAB-ON- A- CHIP & REVERSE TRANSCRIPTASE-PCR, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 16. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2026 (USD MILLION)
  • FIGURE 17. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 18. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MICROARRAYS, 2018-2026 (USD MILLION)
  • FIGURE 19. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MICROARRAYS, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 20. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY QPCR & MULTIPLEXING, 2018-2026 (USD MILLION)
  • FIGURE 21. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY QPCR & MULTIPLEXING, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 22. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2020 VS 2026 (%)
  • FIGURE 23. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2020 VS 2026 (USD MILLION)
  • FIGURE 24. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2026
  • FIGURE 25. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, 2018-2026 (USD MILLION)
  • FIGURE 26. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 27. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER, 2018-2026 (USD MILLION)
  • FIGURE 28. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 29. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, 2018-2026 (USD MILLION)
  • FIGURE 30. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 31. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, 2018-2026 (USD MILLION)
  • FIGURE 32. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 33. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2020 VS 2026 (%)
  • FIGURE 34. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2020 VS 2026 (USD MILLION)
  • FIGURE 35. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2026
  • FIGURE 36. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER SCREENING, 2018-2026 (USD MILLION)
  • FIGURE 37. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER SCREENING, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 38. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2026 (USD MILLION)
  • FIGURE 39. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 40. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROGNOSTICS, 2018-2026 (USD MILLION)
  • FIGURE 41. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROGNOSTICS, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 42. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RISK ANALYSIS, 2018-2026 (USD MILLION)
  • FIGURE 43. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RISK ANALYSIS, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 44. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY THERAPEUTIC MONITORING, 2018-2026 (USD MILLION)
  • FIGURE 45. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY THERAPEUTIC MONITORING, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 46. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2020 VS 2026 (%)
  • FIGURE 47. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2020 VS 2026 (USD MILLION)
  • FIGURE 48. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2026
  • FIGURE 49. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER DEVELOPMENT, 2018-2026 (USD MILLION)
  • FIGURE 50. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER DEVELOPMENT, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 51. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CTC ANALYSIS, 2018-2026 (USD MILLION)
  • FIGURE 52. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CTC ANALYSIS, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 53. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC ANALYSIS, 2018-2026 (USD MILLION)
  • FIGURE 54. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC ANALYSIS, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 55. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC ANALYSIS, 2018-2026 (USD MILLION)
  • FIGURE 56. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC ANALYSIS, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 57. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEOMIC ANALYSIS, 2018-2026 (USD MILLION)
  • FIGURE 58. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEOMIC ANALYSIS, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 59. AMERICAS NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 60. AMERICAS NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 61. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 62. ARGENTINA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 63. BRAZIL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 64. CANADA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 65. MEXICO NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 66. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 67. CALIFORNIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 68. FLORIDA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 69. ILLINOIS NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 70. NEW YORK NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 71. OHIO NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 72. PENNSYLVANIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 73. TEXAS NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 74. ASIA-PACIFIC NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 75. ASIA-PACIFIC NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 76. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 77. CHINA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 78. INDIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 79. INDONESIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 80. JAPAN NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 81. MALAYSIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 82. PHILIPPINES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 83. SOUTH KOREA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 84. THAILAND NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 85. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 86. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 87. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 88. FRANCE NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 89. GERMANY NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 90. ITALY NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 91. NETHERLANDS NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 92. QATAR NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 93. RUSSIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 94. SAUDI ARABIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 95. SOUTH AFRICA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 96. SPAIN NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 97. UNITED ARAB EMIRATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 98. UNITED KINGDOM NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 99. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET: FPNV POSITIONING MATRIX
  • FIGURE 100. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET: SHARE, BY QUADRANT, 2020
  • FIGURE 101. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET: SHARE, BY COMPANY, 2020
  • FIGURE 102. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET, BY TYPE

LIST OF TABLES

  • TABLE 1. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET: MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
  • TABLE 3. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 4. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY DNA MICROARRAYS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 5. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LAB-ON- A- CHIP & REVERSE TRANSCRIPTASE-PCR, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 6. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 7. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MICROARRAYS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 8. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY QPCR & MULTIPLEXING, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 9. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 10. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 11. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 12. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 13. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 14. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 15. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER SCREENING, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 16. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 17. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROGNOSTICS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 18. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RISK ANALYSIS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 19. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY THERAPEUTIC MONITORING, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 20. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 21. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER DEVELOPMENT, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 22. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CTC ANALYSIS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 23. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC ANALYSIS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 24. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC ANALYSIS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 25. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEOMIC ANALYSIS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 26. AMERICAS NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 27. AMERICAS NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 28. AMERICAS NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 29. AMERICAS NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 30. AMERICAS NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 31. ARGENTINA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 32. ARGENTINA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 33. ARGENTINA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 34. ARGENTINA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 35. BRAZIL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 36. BRAZIL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 37. BRAZIL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 38. BRAZIL NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 39. CANADA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 40. CANADA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 41. CANADA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 42. CANADA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 43. MEXICO NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 44. MEXICO NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 45. MEXICO NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 46. MEXICO NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 47. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 48. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 49. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 50. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 51. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 52. CALIFORNIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 53. CALIFORNIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 54. CALIFORNIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 55. CALIFORNIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 56. FLORIDA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 57. FLORIDA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 58. FLORIDA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 59. FLORIDA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 60. ILLINOIS NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 61. ILLINOIS NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 62. ILLINOIS NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 63. ILLINOIS NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 64. NEW YORK NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 65. NEW YORK NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 66. NEW YORK NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 67. NEW YORK NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 68. OHIO NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 69. OHIO NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 70. OHIO NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 71. OHIO NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 72. PENNSYLVANIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 73. PENNSYLVANIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 74. PENNSYLVANIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 75. PENNSYLVANIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 76. TEXAS NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 77. TEXAS NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 78. TEXAS NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 79. TEXAS NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 80. ASIA-PACIFIC NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 81. ASIA-PACIFIC NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 82. ASIA-PACIFIC NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 83. ASIA-PACIFIC NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 84. ASIA-PACIFIC NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 85. CHINA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 86. CHINA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 87. CHINA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 88. CHINA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 89. INDIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 90. INDIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 91. INDIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 92. INDIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 93. INDONESIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 94. INDONESIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 95. INDONESIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 96. INDONESIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 97. JAPAN NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 98. JAPAN NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 99. JAPAN NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 100. JAPAN NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 101. MALAYSIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 102. MALAYSIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 103. MALAYSIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 104. MALAYSIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 105. PHILIPPINES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 106. PHILIPPINES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 107. PHILIPPINES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 108. PHILIPPINES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 109. SOUTH KOREA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 110. SOUTH KOREA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 111. SOUTH KOREA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 112. SOUTH KOREA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 113. THAILAND NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 114. THAILAND NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 115. THAILAND NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 116. THAILAND NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 122. FRANCE NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 123. FRANCE NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 124. FRANCE NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 125. FRANCE NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 126. GERMANY NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 127. GERMANY NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 128. GERMANY NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 129. GERMANY NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 130. ITALY NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 131. ITALY NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 132. ITALY NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 133. ITALY NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 134. NETHERLANDS NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 135. NETHERLANDS NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 136. NETHERLANDS NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 137. NETHERLANDS NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 138. QATAR NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 139. QATAR NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 140. QATAR NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 141. QATAR NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 142. RUSSIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 143. RUSSIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 144. RUSSIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 145. RUSSIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 146. SAUDI ARABIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 147. SAUDI ARABIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 148. SAUDI ARABIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 149. SAUDI ARABIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 150. SOUTH AFRICA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 151. SOUTH AFRICA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 152. SOUTH AFRICA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 153. SOUTH AFRICA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 154. SPAIN NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 155. SPAIN NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 156. SPAIN NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 157. SPAIN NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 158. UNITED ARAB EMIRATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 159. UNITED ARAB EMIRATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 160. UNITED ARAB EMIRATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 161. UNITED ARAB EMIRATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 162. UNITED KINGDOM NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 163. UNITED KINGDOM NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 164. UNITED KINGDOM NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 165. UNITED KINGDOM NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 166. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET: SCORES
  • TABLE 167. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET: BUSINESS STRATEGY
  • TABLE 168. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET: PRODUCT SATISFACTION
  • TABLE 169. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET: RANKING
  • TABLE 170. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET: SHARE, BY QUADRANT, 2020
  • TABLE 171. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET: SHARE, BY COMPANY, 2020
  • TABLE 172. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET: MERGER & ACQUISITION
  • TABLE 173. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
  • TABLE 174. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
  • TABLE 175. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET: INVESTMENT & FUNDING
  • TABLE 176. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET: AWARD, RECOGNITION, & EXPANSION
  • TABLE 177. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET: LICENSE & PRICING
  • TABLE 178. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET: CONTACT DETAILS